<?xml version="1.0" encoding="utf-8"?>
<items><story><date>03:16 03 January 2007 (UTC)</date><text>NEW YORK Jan 3 Biotechnology company Exelixis
Inc. (EXEL.O) said on Wednesday that it has agreed to work with
Genentech Inc. DNA.N on the worldwide co-development of XL518,
an anti-cancer compound. Under the terms of the agreement, Exelixis will receive
upfront and milestone payments totaling $40 million. Exelixis is responsible for developing XL518 through the end
of Phase I, it said. If Genentech exercises its option to
further develop XL518, Exelixis would receive an additional
payment and Genentech would be responsible for further
development, including all further development costs, it said.


</text><link>http://www.reuters.com/article/2007/01/03/exelixis-genentech-idUSWEN167820070103</link><sectors></sectors><title>exelixis signs agreement with genentech</title></story></items>